Abraxis BioScience Files Information Statement in Connection with Its Announced Separation into Two Publicly Traded Companies

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global 
      biopharmaceutical company, today announced the filing of its Form 10 
      registration statement in connection with the proposed plan to separate 
      its proprietary business -- Abraxis Oncology and Abraxis Research (the 
      new Abraxis BioScience) -- from its hospital-based business -- Abraxis 
      Pharmaceutical Products (APP). The information statement outlines the 
      operations of the proprietary business and can be found at the SEC’s 
      Web site under the company name “New Abraxis, 
      Inc.” The company will apply to list the 
      securities on the NASDAQ Global Market under the symbol “ABII.” 
      Following is a link to the information statement on the SEC’s 
      Web site: http://www.sec.gov/Archives/edgar/data/1409012/000119312507177626/ 
      dex991.htm.
    
    
      (Due to its length, this URL may need to be copied/pasted into your 
      Internet browser's address field. Remove the extra space if one exists.)
    
    
      About Abraxis BioScience, Inc.
    
    
      Abraxis BioScience, Inc. is an integrated global biopharmaceutical 
      company dedicated to meeting the needs of critically ill patients. The 
      company develops, manufactures and markets one of the broadest 
      portfolios of injectable products and leverages revolutionary technology 
      such as its nab™ platform to discover 
      and deliver breakthrough therapeutics that transform the treatment of 
      cancer and other life-threatening diseases. The first FDA approved 
      product to use this nab platform, ABRAXANE®, 
      was launched in 2005 for the treatment of metastatic breast cancer. 
      Abraxis trades on the NASDAQ Global Market under the symbol ABBI. For 
      more information about the company and its products, please visit www.abraxisbio.com.